|
| Press Releases |
|
 |
|
| Tuesday, July 23, 2024 |
|
|
Eisai to Present Dual-Acting Lecanemab Three-Year Efficacy and Safety Data and Discuss Long-Term Outcomes of Continued Treatment at the Alzheimer's Association International Conference 2024 |
| The conference will be held in Philadelphia and virtually from July 28 to August 1, 2024. Eisai will present data and research in four (4) oral and 15 poster presentations at the meeting and will host two (2) sessions on lecanemab. more info >> |
|
| Friday, July 12, 2024 |
|
|
"LEQEMBI" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Israel |
| Eisai Co., Ltd. and Biogen Inc. announced today that humanized anti-soluble aggregated amyloid-beta (Abeta) monoclonal antibody "LEQEMBI" (generic name: lecanemab) has been approved in Israel as a treatment of Alzheimer's disease (AD). more info >> |
|
| Thursday, July 11, 2024 |
|
|
LEQEMBI (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Hong Kong |
| Eisai Co., Ltd. and Biogen Inc. announced today that the Department of Health in HongKong has approved humanized anti-soluble aggregated amyloid-beta (Abeta;) monoclonal antibody "LEQEMBI" (brand name in Hong Kong: generic name: lecanemab) for treatment of Alzheimer's disease (AD). more info >> |
|
| Tuesday, July 2, 2024 |
|
|
Eisai Announces Move to Solo Development and Commercialization of Farletuzumab Ecteribulin (FZEC) Antibody Drug Conjugate (ADC) |
| Eisai Co., Ltd. announced today that it has agreed to end its global strategic collaboration with Bristol Myers Squibb for the co-development and co-commercialization of farletuzumab ecteribulin (FZEC), formerly known as MORAb-202, a folate receptor alpha (FRα)-targeting antibody drug conjugate (ADC) due to ongoing portfolio prioritization efforts within Bristol Myers Squibb. more info >> |
|
| Friday, June 28, 2024 |
|
|
Eisai: "LEQEMBI" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in China |
| China is the third country to launch LEQEMBI following the United States and Japan. more info >> |
|
| Friday, June 21, 2024 |
|
|
Eisai Continues Contract for FY2024 Dementia Examination Project by Tokyo Bunkyo City |
| Eisai Co., Ltd. announced today that the company has achieved the pre-set performance indicators in FY2023 for the dementia examination project in Bunkyo City, Tokyo, which the company has been commissioned to conduct in order to raise awareness of dementia and promote early detection, and will continue the commission for this project in FY2024. more info >> |
|
| Monday, June 10, 2024 |
|
|
FDA Accepts Eisai's Filing of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease |
| Eisai Co., Ltd. and Biogen Inc. announced today that that the U.S. Food and Drug Administration (FDA) has accepted Eisai's Supplemental Biologics License Application (sBLA) for monthly lecanemab-irmb (U.S. brand name: LEQEMBI) intravenous (IV) maintenance dosing. more info >> |
|
| Monday, June 3, 2024 |
|
|
Eisai Named to List of The Time 100 Most Influential Companies |
| TIME reveals the TIME100 Most Influential Companies list, highlighting companies making an extraordinary impact around the world. more info >> |
|
|
Eisai Strengthens Venture Investment Business Aimed at Accelerating Drug Discovery Innovation and Establishment of Ecosystem Platform |
| Eisai Co., Ltd. announced today that the company decided to strengthen and continue its venture investment business, which launched in 2019, with the aim of discovering innovative technologies and services, supporting venture businesses with such technologies and partnering with those businesses in the future, so as to accelerate drug discovery innovation and the establishment of the ecosystem platform. more info >> |
|
| Tuesday, May 28, 2024 |
|
|
LEQEMBI (lecanemab) Approved for the Treatment of Alzheimer's Disease in South Korea |
| Eisai Co., Ltd. and Biogen Inc. announced today that the Ministry of Food and Drug Safety (MFDS) in South Korea has approved humanized anti-soluble aggregated amyloid-beta (Abeta) monoclonal antibody "LEQEMBI" (lecanemab) for treatment in adult patients with mild cognitive impairment due to Alzheimer's disease (AD) or mild AD (early AD). more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
The University of Osaka D3 Center Commences Operation of New Computing and Data Infrastructure Built by NEC
Sept 12, 2025 15:08 JST
|
|
|
GR Yaris "Aero performance package" Set for Japan Launch
Sept 12, 2025 14:40 JST
|
|
|
Mitsubishi Heavy Industries Achieves Target Performance at Pilot Plant for Bioethanol Membrane Dehydration Systems
Sept 12, 2025 14:19 JST
|
|
|
"New Answers to Dementia" Eisai Releases Concept Movie and New Content on Campaign Website for Dementia Month
Sept 12, 2025 13:20 JST
|
|
|
TANAKA PRECIOUS METAL TECHNOLOGIES Succeeds in Developing High-Performance Palladium Alloy Hydrogen Permeable Membrane Operable in the Low-Temperature Range of 300 degrees C
Sept 12, 2025 11:00 JST
|
|
|
Among Migrating Nurses, Survey Shows High Satisfaction Rates for Those Who Use a Certified Ethical Recruiter
Sept 12, 2025 05:00 HKT/SGT
|
|
|
Doubleview Gold Corp Announces Important High-Grade Copper and Gold Intercepts at Hat Polymetallic Deposit in Northwestern British Columbia
Sept 11, 2025 22:29 HKT/SGT
|
|
|
The 10th Belt and Road Summit concludes successfully
Sept 11, 2025 20:40 HKT/SGT
|
|
|
CO2NNEX(R) Digital Platform for Transfer and Management of e-Methane Clean Gas Certificates to Be Utilized in Nagaoka Methanation Demonstration
Sept 11, 2025 20:37 JST
|
|
|
Hitachi accelerates growth with major U.S. investments in advanced manufacturing, electrification and workforce development
Sept 11, 2025 18:35 JST
|
|
|
GlobalLogic and Ericsson Deploy Private 5G Network at Hitachi Rail's State-of the-Art Digital Factory
Sept 11, 2025 17:24 JST
|
|
|
A Sparkling New Chapter: Spritzer's First-Ever Mini-Drama Series Stars New Brand Ambassador Anna Jobling
Sept 11, 2025 16:23 HKT/SGT
|
|
|
GlobalLogic and Flexware Innovation Announce Major Deployment of LIFT at Hitachi Rail's State-of-the-Art Train Manufacturing Facility
Sept 11, 2025 16:46 JST
|
|
|
JCB Unveils New Brand Message in Vietnam: "Japan Cung Ban" 
Sept 11, 2025 13:00 JST
|
|
|
Kawasaki City becomes first dekokatsu subsidy municipality for promoting decarbonization lifestyle promotion project
Sept 11, 2025 10:35 JST
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
